Lyophilized whole blood controls for G6PD (glucose-6-phosphate dehydrogenase) and preparation method of lyophilized whole blood controls

Abstract

The invention discloses lyophilized whole blood controls for G6PD (glucose-6-phosphate dehydrogenase) and a preparation method of the lyophilized whole blood controls. The controls are lyophilized products prepared from CPD whole blood matrixes and G6PD. The preparation method of the lyophilized whole blood controls comprises steps as follows: red blood cells and plasma of the CPD whole blood matrixes are separated centrifugally; red blood cell hemolysates are prepared with a physical method and are mixed with hemolysates in different ratios, and the CPD whole blood matrixes are obtained; different quantities of G6PD are added to the whole blood matrixes, the control containing G6PD in a normal level and the control containing G6PD in a deficient level are prepared, the two controls are subpackaged and subjected to lyophilization and vacuum capping, and the lyophilized whole blood controls for G6PD are obtained. The controls have good product homogeneity, good long-term sample storage stability and good stability after redissolving, are not influenced by factors such as transportation, temperature and the like, are wide in applicable range, can be suitable for different brands of quantitative detection kits, can meet the clinical quality control requirement for G6PD detection, and can improve the accuracy of a clinical sample detection result.

Description

technical field [0001] The invention relates to the technical field of medical testing, in particular to a glucose-6-phosphate dehydrogenase freeze-dried whole blood quality control product and a preparation method thereof. Background technique [0002] Glucose-6-phosphate dehydrogenase (G6PD for short) is a housekeeping enzyme present in all cells and tissues, and it is the initial enzyme of the pentose phosphate bypass metabolism, which provides pentose Used for nucleic acid synthesis, to maintain reduced glutathione to generate reduced coenzyme II (NADPH), maintain the reducing ability of red blood cells, and prevent damage to red blood cells by substances such as hydrogen peroxide. G6PD deficiency is the most common hereditary enzyme deficiency disease in humans. It is inherited in an incompletely dominant manner on the X chromosome. Its clinical changes are relatively large, ranging from asymptomatic to acute hemolysis, favism, and chronic non-spherical cells caused by ...

AI Technical Summary

Problems solved by technology

Quality control products provided by commercial reagent manufacturers cannot be used for G6PD quantitative testing

Images